Search

Your search keyword '"Gallardo ME"' showing total 67 results

Search Constraints

Start Over You searched for: Author "Gallardo ME" Remove constraint Author: "Gallardo ME"
67 results on '"Gallardo ME"'

Search Results

1. Establishment of a human iPSC line, IISHDOi004-A, from a patient with Usher syndrome associated with the mutation c.2276G > T; p.Cys759Phe in the USH2A gene

3. OPA1 mutations induce mitochondrial DNA instability and optic atrophy 'plus' phenotypes

4. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain

5. Creation of an Isogenic Human iPSC-Based RGC Model of Dominant Optic Atrophy Harboring the Pathogenic Variant c.1861C>T (p.Gln621Ter) in the OPA1 Gene.

6. Hereditary Optic Neuropathies: A Systematic Review on the Interplay between Biomaterials and Induced Pluripotent Stem Cells.

7. Creation of an iPSC-Based Skeletal Muscle Model of McArdle Disease Harbouring the Mutation c.2392T>C (p.Trp798Arg) in the PYGM Gene.

8. Generation of the First Human In Vitro Model for McArdle Disease Based on iPSC Technology.

9. Development and Validation of the Mexican Public Open Spaces Tool (MexPOS).

10. Hereditary Optic Neuropathies: Induced Pluripotent Stem Cell-Based 2D/3D Approaches.

11. Generation of the iPSC line IISHDOi007-A from peripheral blood mononuclear cells from a patient with McArdle disease harbouring the mutation c.2392 T > C; p.Trp798Arg.

12. Perception of Safety and Its Association With Physical Activity in Adolescents in Mexico.

13. Mitochondrial Dysfunction and Calcium Dysregulation in Leigh Syndrome Induced Pluripotent Stem Cell Derived Neurons.

15. The Challenge of Bringing iPSCs to the Patient.

16. The mutation m.13513G>A impairs cardiac function, favoring a neuroectoderm commitment, in a mutant-load dependent way.

17. Derivation of a human DOA iPSC line, IISHDOi006-A, with a mutation in the ACO2 gene: c.1999G>A; p.Glu667Lys.

18. iPSCs: A powerful tool for skeletal muscle tissue engineering.

19. Derivation of an aged mouse induced pluripotent stem cell line, IISHDOi005-A.

20. Association between urbanicity and physical activity in Mexican adolescents: The use of a composite urbanicity measure.

21. Establishment of a human iPSC line, IISHDOi004-A, from a patient with Usher syndrome associated with the mutation c.2276G>T; p.Cys759Phe in the USH2A gene.

22. Generation and characterization of two human iPSC lines from patients with methylmalonic acidemia cblB type.

23. Generation of a human iPSC line, IISHDOi002-A, with a 46, XY/47, XYY mosaicism and belonging to an African mitochondrial haplogroup.

24. Establishment of a human DOA 'plus' iPSC line, IISHDOi003-A, with the mutation in the OPA1 gene: c.1635C>A; p.Ser545Arg.

25. Adjuvant treatment for pancreatic ductal carcinoma.

26. Establishment of a human iPSC line (IISHDOi001-A) from a patient with McArdle disease.

27. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain.

28. The Associations Between Urbanicity and Physical Activity and Sitting Time in Mexico.

29. iPSCs, a Future Tool for Therapeutic Intervention in Mitochondrial Disorders: Pros and Cons.

30. Generating Rho-0 Cells Using Mesenchymal Stem Cell Lines.

31. Reprogramming for Cardiac Regeneration-Strategies for Innovation.

32. iPSCs-based anti-aging therapies: Recent discoveries and future challenges.

33. Generation of a human iPSC line from a patient with Leigh syndrome caused by a mutation in the MT-ATP6 gene.

34. Generation of a human iPSC line from a patient with an optic atrophy 'plus' phenotype due to a mutation in the OPA1 gene.

35. IPSCs, a Promising Tool to Restore Muscle Atrophy.

36. Generation of a human control iPSC line with a European mitochondrial haplogroup U background.

37. Generation of a human iPSC line from a patient with a defect of intergenomic communication.

38. Generation of a human iPSC line from a patient with a mitochondrial encephalopathy due to mutations in the GFM1 gene.

39. Enhanced tumorigenicity by mitochondrial DNA mild mutations.

40. Co-occurrence of four nucleotide changes associated with an adult mitochondrial ataxia phenotype.

41. Glutamyl-tRNAGln amidotransferase is essential for mammalian mitochondrial translation in vivo.

42. The pathogenicity scoring system for mitochondrial tRNA mutations revisited.

43. The thyroid hormone receptor β induces DNA damage and premature senescence.

44. Cardiac dysfunction in mitochondrial disease. Clinical and molecular features.

45. Mitochondrial tRNA valine as a recurrent target for mutations involved in mitochondrial cardiomyopathies.

46. Mitochondrial haplogroups associated with end-stage heart failure and coronary allograft vasculopathy in heart transplant patients.

47. Genetic basis of end-stage hypertrophic cardiomyopathy.

48. Evolution meets disease: penetrance and functional epistasis of mitochondrial tRNA mutations.

49. [Mitochondrial DNA depletion and POLG mutations in a patient with sensory ataxia, dysarthria and ophthalmoplegia].

50. MidA is a putative methyltransferase that is required for mitochondrial complex I function.

Catalog

Books, media, physical & digital resources